WITHDRAWN: Etidronate for treating and preventing postmenopausal osteoporosis

Area of Science:

• Bone Metabolism and Osteoporosis Research
• Pharmacological Interventions for Bone Health

Background:

• Osteoporosis is characterized by reduced bone mass and increased fracture risk.
• Etidronate is a bisphosphonate option for managing osteoporosis and reducing fracture incidence.

Purpose of the Study:

• To systematically review the efficacy of etidronate in postmenopausal women.
• Evaluate etidronate's impact on bone density, fracture rates, and toxicity.

Main Methods:

• Systematic review of MEDLINE, citations, and conference proceedings (1966-1998).
• Inclusion of 13 randomized trials with 1010 participants comparing etidronate to placebo or calcium/vitamin D.
• Independent assessment of methodological quality and data abstraction by three reviewers.

Main Results:

• Etidronate significantly increased bone density: lumbar spine by 4.27%, femoral neck by 2.19%, and total body by 0.97% after three years.
• A reduction in vertebral fractures was observed (pooled relative risk 0.60%).
• No significant effect on non-vertebral fractures was found (pooled relative risk 1.00).

Conclusions:

• Etidronate demonstrates efficacy in increasing bone mineral density at key skeletal sites.
• The drug is associated with a reduction in vertebral fractures but not non-vertebral fractures.
• Findings support etidronate's role in managing osteoporosis, particularly for vertebral fracture prevention.